Pfizer: Commission approves alopecia areata
(CercleFinance.com) - Pfizer has announced that the European Commission (EC) has granted marketing authorisation for LITFULO (ritlecitinib) in the treatment of severe alopecia areata in adults and adolescents aged 12 years and older.
LITFULO, an oral capsule administered once a day, is the first drug authorised by the EC to treat people with severe alopecia areata from the age of 12.
Today's approval of LITFULO in Europe is an important milestone for patients as young as 12 with severe hair loss due to alopecia areata, as they now have the opportunity to achieve significant hair regrowth, Pfizer said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.